Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2016 - 2025)
Vanda Pharmaceuticals' Gains from Investment Securities history spans 15 years, with the latest figure at -$2.9 million for Q4 2025.
- On a quarterly basis, Gains from Investment Securities changed N/A to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.9 million, a N/A change, with the full-year FY2025 number at -$1.9 million, changed N/A from a year prior.
- Gains from Investment Securities hit -$2.9 million in Q4 2025 for Vanda Pharmaceuticals, down from $81000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for VNDA hit a ceiling of $915000.0 in Q1 2025 and a floor of -$2.9 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged -$513875.0 across 4 years, with a median of -$529000.0 in 2021.
- The widest YoY moves for Gains from Investment Securities: up 180.21% in 2023, down 100.91% in 2023.
- Tracing VNDA's Gains from Investment Securities over 4 years: stood at -$506000.0 in 2021, then tumbled by 66.8% to -$844000.0 in 2022, then skyrocketed by 180.21% to $677000.0 in 2023, then crashed by 522.16% to -$2.9 million in 2025.
- Business Quant data shows Gains from Investment Securities for VNDA at -$2.9 million in Q4 2025, $81000.0 in Q3 2025, and -$81000.0 in Q2 2025.